Nelson Capital Management’s Myriad Genetics MYGN Stock Holding History

Nelson Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-80	Closed	-$2K	–	265
2017 Q2	$2K	Buy	+80	New	+$1.7K	﹤0.01%	273

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Nelson Capital Management's MYGN Position: Q3 2017 in Review

Nelson Capital Management sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 80 shares — an estimated $2K sold.

Nelson Capital Management first reported a position in MYGN in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

Nelson Capital Management reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
Nelson Capital Management sold 80 Myriad Genetics shares in Q3 2017, an estimated $2K.
Nelson Capital Management first reported a position in Myriad Genetics in Q2 2017 and held it in 1 quarter.
Nelson Capital Management's Myriad Genetics position peaked at $2K in Q2 2017.
220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Nelson Capital Management's 13F filing for Q3 2017, filed 2 Nov 2017.